Krensavage Asset Management’s BioNTech BNTX Stock Holding History

Krensavage Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.29M	Sell	59,523 -40,000	-40%	-$4.11M	2.07%	13
2025 Q4	$9.47M	Buy	99,523 +20,157	+25%	+$2.03M	3.35%	12
2025 Q3	$7.83M	Buy	79,366 +5,984	+8%	+$640K	3.33%	12
2025 Q2	$7.81M	Sell	73,382 -14,181	-16%	-$1.43M	4.14%	10
2025 Q1	$7.97M	Sell	87,563 -1,100	-1%	-$123K	4.41%	10
2024 Q4	$10.1M	Sell	88,663 -4,920	-5%	-$561K	5.98%	8
2024 Q3	$11.1M	Sell	93,583 -38,710	-29%	-$3.56M	6.23%	7
2024 Q2	$10.6M	Buy	132,293 +12,293	+10%	+$1.12M	4.88%	8
2024 Q1	$11.1M	Buy	+120,000	New	+$11.5M	4.91%	9

Other funds holding BNTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Krensavage Asset Management's BNTX Position: Q1 2026 in Review

Krensavage Asset Management reduced its BioNTech (BNTX) stake by 40% in Q1 2026, selling an estimated $4.11M and leaving 59,523 shares worth $5.29M. The position accounts for 2.07% of the portfolio, ranked #13.

Krensavage Asset Management first reported a position in BNTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $11.1M in Q3 2024. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

Krensavage Asset Management held 59,523 shares of BioNTech worth $5.29M as of Q1 2026.
Krensavage Asset Management sold 40,000 BioNTech shares in Q1 2026, an estimated $4.11M.
BioNTech made up 2.07% of Krensavage Asset Management's portfolio in Q1 2026, its #13 holding.
Krensavage Asset Management first reported a position in BioNTech in Q1 2024 and has held it in 9 quarters since.
Krensavage Asset Management's BioNTech position peaked at $11.1M in Q3 2024.
272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on Krensavage Asset Management's 13F filing for Q1 2026, filed 15 May 2026.